Cochrane · systematic review · CD013306
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis
Battle, CE, Abdul-Rahim, AH, Shenkin, SD, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
19
current version
GRADE rated
19
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 5.3%Low 4 · 21.1%Moderate 10 · 52.6%High 4 · 21.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Donepezil 5 mg compared to placebo for vascular dementia and other vascular cognitive impairments
Population: vascular dementia and other vascular cognitive impairments
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function: ADAS‐Cog at 24 weeksScale from: 0 to 70 Donepezil 5 mg vs placebo | no estimate extracted | 3 studies · 1601 participants | High |
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale Donepezil 5 mg vs placebo | OR 1.58 [1.1, 2.27] | 2 studies · 712 participants | High |
Functional performance and activities of daily living: ADFACS at 24 weeks 16‐item score ranging from 0 to 54 Donepezil 5 mg vs placebo | no estimate extracted | 2 studies · 798 participants | Moderate Downgraded: imprecision |
Adverse events (all reported adverse events grouped) at 24 weeks Donepezil 5 mg vs placebo | OR 1.22 [0.94, 1.58] | 3 studies · 1772 participants | Moderate Downgraded: imprecision |
Serious adverse events (excluding death) at 24 weeks Donepezil 5 mg vs placebo | OR 0.94 [0.72, 1.22] | 3 studies · 1772 participants | Moderate Downgraded: imprecision |
Donepezil 10 mg compared to placebo for vascular dementia and other vascular cognitive impairments
Population: vascular dementia and other vascular cognitive impairments
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function: ADAS‐Cog at 24 weeksScale from: 0 to 70 Donepezil 10 mg vs placebo | no estimate extracted | 2 studies · 608 participants | Moderate Downgraded: imprecision |
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale Donepezil 10 mg vs placebo | OR 1.15 [0.78, 1.7] | 2 studies · 699 participants | Moderate Downgraded: imprecision |
Functional performance and activities of daily living: ADFACS at 24 weeks 16‐item score ranging from 0 to 54 Donepezil 10 mg vs placebo | no estimate extracted | 2 studies · 813 participants | Moderate Downgraded: imprecision |
Adverse events (all adverse events) at 24 weeks Donepezil 10 mg vs placebo | OR 1.95 [1.2, 3.15] | 2 studies · 813 participants | High |
Serious adverse events (excluding death) at 24 weeks Donepezil 10 mg vs placebo | OR 1.15 [0.81, 1.64] | 2 studies · 813 participants | Moderate Downgraded: imprecision |
Rivastigmine compared to placebo for vascular dementia and other vascular cognitive impairments
Population: vascular dementia and other vascular cognitive impairments
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function: ADAS‐Cog at 24 to 26 weeksScale from: 0 to 70 Rivastigmine vs placebo | no estimate extracted | 2 studies · 748 participants | Low Downgraded: imprecision, inconsistency |
Functional performance and activities of daily living at 24 to 26 weeks: ADCS‐ADL and IADL scales Rivastigmine vs placebo | no estimate extracted | 3 studies · 800 participants | Low Downgraded: imprecision |
Adverse events (all adverse events) at 24 to 26 weeks Rivastigmine vs placebo | OR 3.21 [0.36, 28.88] | 3 studies · 831 participants | Very low Downgraded: imprecision, inconsistency |
Serious adverse events (excluding death) at 24 to 26 weeks Rivastigmine vs placebo | OR 1.42 [0.9, 2.25] | 2 studies · 622 participants | Low Downgraded: imprecision |
Galantamine compared to placebo for vascular dementia and other vascular cognitive impairments
Population: vascular dementia and other vascular cognitive impairments
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function: ADAS‐Cog at 26 weeks Scale from: 0 to 70 Galantamine vs placebo | no estimate extracted | 2 studies · 1188 participants | Moderate Downgraded: inconsistency |
Clinical global impression: CIBIC‐Plus (Improvement) at 26 weeks Galantamine vs placebo | OR 1.32 [1.03, 1.7] | 2 studies · 1326 participants | High |
Functional performance and activities of daily living at 26 weeks ADCS‐ADL and DAD Galantamine vs placebo | no estimate extracted | 2 studies · 1174 participants | Low Downgraded: imprecision |
Adverse events (all adverse events) at 26 weeks Galantamine vs placebo | OR 1.57 [1.02, 2.43] | 2 studies · 1378 participants | Moderate Downgraded: imprecision |
Serious adverse events (excluding deaths) at 26 weeks Galantamine vs placebo | OR 1.12 [0.78, 1.59] | 1 study · 786 participants | Moderate Downgraded: imprecision |